EBV LMP-1 Antibody (3H2104,a,b,c): sc-71023

EBV LMP-1 Antibody (3H2104,a,b,c) is a mouse monoclonal IgG1 antibody that detects the EBV LMP-1 protein of Epstein-Barr Virus origin by immunofluorescence (IF) and immunohistochemistry with paraffin-embedded sections (IHCP). Anti-EBV LMP-1 antibody (3H2104,a,b,c) is available as a non-conjugated format. EBV LMP-1 protein plays a crucial role in the pathogenesis of Epstein-Barr Virus, acting as a viral oncogene that mimics CD40 signaling, which is essential for B cell activation and proliferation. By engaging the CD40 receptor, LMP-1 promotes cell survival and proliferation, contributing to the transformation of infected B cells and the potential development of malignancies such as Burkitt lymphoma and nasopharyngeal carcinoma. Understanding the function of LMP-1 is vital for elucidating the mechanisms of EBV-associated diseases and developing targeted therapies. As one of the most common human viruses, EBV infects approximately 90% of the population, primarily targeting B lymphocytes, and can lead to conditions ranging from asymptomatic infections to serious diseases like infectious mononucleosis. The linear genome of EBV circularizes upon entering the host cell, existing as an episome, and can undergo either a lytic cycle, producing infectious virions, or a latent cycle, allowing the virus to persist in the host for years.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

EBV LMP-1 Antibody (3H2104,a,b,c) References:

1. Epstein-barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma.  |  Ruf, IK., et al. 1999. Mol Cell Biol. 19: 1651-60. PMID: 10022853
2. Epstein-Barr Viral Antigens Used in the Diagnosis of Nasopharyngeal Carcinoma.  |  Gan, YY., et al. 1996. J Biomed Sci. 3: 159-169. PMID: 11725096
3. Cell target genes of Epstein-Barr virus transcription factor EBNA-2: induction of the p55alpha regulatory subunit of PI3-kinase and its role in survival of EREB2.5 cells.  |  Spender, LC., et al. 2006. J Gen Virol. 87: 2859-2867. PMID: 16963743
4. Serodiagnosis of infectious mononucleosis by using recombinant Epstein-Barr virus antigens and enzyme-linked immunosorbent assay technology.  |  Gorgievski-Hrisoho, M., et al. 1990. J Clin Microbiol. 28: 2305-11. PMID: 2172287
5. Characterization of the restricted component of Epstein-Barr virus early antigens as a cytoplasmic filamentous protein.  |  Luka, J., et al. 1986. J Virol. 58: 748-56. PMID: 2422401
6. Neutralization of Epstein-Barr virus-induced ribonucleotide reductase with antibody to the major restricted early antigen polypeptide.  |  Goldschmidts, WL., et al. 1989. Virology. 170: 330-3. PMID: 2541553
7. Epstein-Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update.  |  Smatti, MK., et al. 2018. Front Oncol. 8: 211. PMID: 29951372
8. Co-expression of low-risk HPV E6/E7 and EBV LMP-1 leads to precancerous lesions by DNA damage.  |  Uehara, K., et al. 2021. BMC Cancer. 21: 688. PMID: 34112111
9. Epstein-Barr Virus Detection and LMP-1 Expression in Thai Patients with Oral Squamous Cell Carcinoma.  |  Rungraungrayabkul, D., et al. 2023. Head Neck Pathol. 17: 210-217. PMID: 36255669
10. Genetic variability and mutation of Epstein‒Barr virus (EBV)-encoded LMP-1 and BHRF-1 genes in EBV-infected patients: identification of precise targets for development of personalized EBV vaccines.  |  Wang, Y., et al. 2023. Virus Genes. 59: 541-553. PMID: 37243920
11. Evolutionary analysis of LMP-1 genetic diversity in EBV-associated nasopharyngeal carcinoma: Bioinformatic insights into oncogenic potential.  |  Alanazi, AE., et al. 2024. Infect Genet Evol. 120: 105586. PMID: 38508363
12. Association between Epstein-Barr virus LMP-1 and Hodgkin lymphoma LMP-1 mechanisms in Hodgkin lymphoma development.  |  Oliveira, LOD., et al. 2024. Rev Med Virol. 34: e2561. PMID: 38877989